Treatment Burden, Clinic Visits, and the Subcutaneous Amivantamab Formulation

Dr. Gumbleton turns to treatment burden, a central concern for Mrs. Chen given that she works full time as a teacher and lives about 75 minutes from the clinic.

Amivantamab dosing is weekly for the first month, which Dr. Gumbleton acknowledges is a meaningful number of trips up front for a patient with her commute. After the initial period, the development of subcutaneous (SC) amivantamab has materially changed the experience: in his practice, SC administration is a quick infusion lasting just a few minutes, with no significant administration-related reactions observed in his patients. Treatment then transitions to a monthly schedule, offering a clear benefit over time.

By contrast, the osimertinib-plus-chemotherapy regimen starts every 3 weeks from the outset. Although it is a somewhat easier schedule than weekly amivantamab in the first month, it remains every 3 weeks over time, at least until chemotherapy is discontinued due to cumulative toxicity. Ideally, patients continue chemotherapy for more cycles because outcomes appear to improve with greater chemotherapy exposure, meaning those every-3-week visits will add up.

Taken together, the short-term burden is higher with weekly amivantamab, but the long-term burden is lower once patients transition to monthly SC dosing. For a patient like Mrs. Chen with a long commute and a stated preference to minimize time away from work, this longer-term advantage is a relevant consideration.

In the next episode, “Sequencing and Preserving Options After Progression”, Dr. Gumbleton closes the case with how the first-line choice affects later-line options.